Fintel reports that on August 15, 2025, JP Morgan upgraded their outlook for Precigen (NasdaqGS:PGEN) from Underweight to ...

Earlier today, it was announced that Precigen’s PAPZIMEOS (formerly PRGN-2012) was FDA-approved for adults with RRP. Read why ...

Precigen (PGEN) stock jumps as the FDA approves the company's gene therapy Papzimeos for adults with recurrent respiratory ...

The Police Regional Office Cordillera Administrative Region (PRO CAR) earned the prestigious title of Best Police Regional ...

Precigen's immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for ...

Precigen's Papzimeos wins FDA approval as the first therapy for adult recurrent respiratory papillomatosis, showing durable results in clinical trials.

The following are the most active stocks for the pre-market session: Precigen, Inc. (PGEN) is +1.02 at $2.87, with 26,862,424 shares traded.

The US Food and Drug Administration (FDA) has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults ...

Aug 15 (Reuters) - Precigen's (PGEN.O), opens new tab immunotherapy for a rare respiratory disease has become the first treatment to win U.S. regulatory approval for the condition, which typically ...

"With the landmark FDA approval of PAPZIMEOS and broad label, all adult RRP patients are now eligible for access to the first and only approved therapy that targets the root cause of the disease," ...